FDA Approval Could Send Mylan (MYL) to New High

Expect to see some heavy volume today on Mylan Inc. (Nasdaq: MYL) today. Mylan, Inc., one of the leading generic and specialty pharmaceutical companies worldwide, was granted tentative approval, under the President Obama’s Emergency Plan for AIDS Relief, from the FDA  for Abacavir Sulfate and Lamivudine Tablets, 60 mg/30 mg. Add MYL to your list of stocks to watch immediately.

Used for treating children with HIV/AIDS, approval of Abacavir Sulfate and Lamivudine further supports the company’s mission to continue expanding access to high quality medicine around the world, which is especially crucial for children living with HIV/AIDS.

MYL One Year Stock Chart:


Mylan Stock has been on a major upward trend since hitting 15.49 on October 4th of last year. With its 52-Week high within reach, expect to see some heavy volume trading on MYL today.

Mylan maintains one of the industry’s broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world’s largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies.

Last updated by at .

  Recent Penny Stock News